Streetbeat News

Regulatory

AAPL

Over the weekend, the budget bill was ratified, OPEC+ decided to roll forward production quota cuts into 2024, and Saudi Arabia announced a voluntary one million barrel per day output cut. Tesla CEO Elon Musk discussed his work habits and sleep requirements, while former Treasury Secretary Larry Summers suggested a potential rate hike. Apple is expected to unveil a mixed-reality headset at its Worldwide Developers Conference 2023.

Portfolio Pulse from Shanthi Rexaline

June 05, 2023 | 12:29 pm

SPIKE

UVXY

The CBOE Volatility Index (VIX) has reached nearly 2-year lows, trading at its lowest level since July 2021. This comes amid concerns of a potential recession and ahead of a key Federal Reserve meeting on June 13 and 14. Traders can trade the volatility using MIAX's SPIKES Volatility products and ProShares Ultra VIX Short Term Futures ETF (UVXY).

Portfolio Pulse from Melanie Schaffer

June 05, 2023 | 12:26 pm

BIOC

Biocept presented a scientific poster at the 2023 ASCO Meeting, highlighting a real-world retrospective study that showed increased sensitivity for CNSide relative to standard cerebral spinal fluid (CSF) cytology in detecting leptomeningeal metastases.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:25 pm

DG

Dollar General has filed for a mixed shelf offering with the SEC, but the size of the offering has not been disclosed.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:24 pm

DAWN

Day One Biopharmaceuticals (NASDAQ:DAWN) announced positive data from the Phase 2 FIREFLY-1 trial of tovorafenib (DAY101) at the 2023 ASCO Annual Meeting. The company also initiated a rolling New Drug Application (NDA) to the FDA for tovorafenib as a monotherapy in pediatric low-grade glioma (pLGG). DAWN shares are up 23.20% in premarket trading.

Portfolio Pulse from Vandana Singh

June 05, 2023 | 12:23 pm

BAC

C

GS

JPM

MS

WFC

US regulators are planning to enforce stricter capital requirements on large banks, potentially increasing overall capital requirements by 20%. This move aims to enhance financial stability following recent midsize bank failures and may be introduced as early as this month.

Portfolio Pulse from Vandana Singh

June 05, 2023 | 12:19 pm

PRTG

Portage Biotech presented updated interim data for its lead iNKT Engager, PORT-2, at the 2023 ASCO Meeting, showing early evidence of single agent activity and meaningful reduction of target lesions. The company plans to expand the Phase 1 trial to evaluate higher dose levels, with data expected by the end of 2023.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:18 pm

BCEL

Atreca presents data from its ongoing Phase 1b study of ATRC-101 in patients with select advanced solid tumors at the 2023 ASCO Meeting. Clinical activity was observed in multiple tumor types, with longer progression-free survival in patients with high target expression. ATRC-101 continues to be well-tolerated, and Phase 2 go/no-go decisions are expected by the end of the year.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:05 pm

ENVB

Enveric Biosciences has received a Notice of Allowance from the USPTO for its EVM301 series of drug candidates, which are designed to address various central nervous system disorders.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:03 pm

NEXI

NexImmune presented initial data from its NEXI-001 Phase 1 trial for relapsed/refractory post allo-HSCT AML at the 2023 ASCO Meeting. The trial showed a favorable safety profile and robust immune response, with one patient achieving no evidence of disease 7 months post-infusion.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2023 | 12:02 pm